Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin heavy diversity 5-18 (IGHD5-18) is one of several DH (diversity heavy) gene segments located within the immunoglobulin heavy-chain (IGH) locus on human chromosome 14. DH segments are required for the assembly of variable regions of immunoglobulins during V(D)J recombination in developing B cells. This process allows the immune system to generate a highly diverse repertoire of antibodies, which is central to adaptive immunity. IGHD5-18 itself is not a protein or receptor; rather, it is a short DNA sequence that gets recombined together with IGHV (heavy variable) and IGHJ (heavy joining) gene segments to form a unique variable domain coding sequence for the immunoglobulin heavy chain[1][2][3][5]. This genetic recombination is necessary for generating antibody diversity but does not make IGHD5-18 a therapeutic target. Key details: - IGHD5-18 is a DH segment, meaning its biological role is to contribute to variable domain diversity in immunoglobulin heavy chains through genetic recombination[1][5]. - It is not expressed as a standalone protein, receptor, or functional entity. - No drugs or biomarker applications target IGHD5-18 specifically. - Not associated with safety concerns or therapeutic strategies. If you seek information about therapeutic targets, focus on the immunoglobulin proteins produced via V(D)J recombination or the receptors/enzymes that mediate these processes, rather than DH gene segments themselves.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoglobulin heavy diversity 5-18 (IGHD5-18).